Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Anti—Tumor Necrosis Factor Antibody Reduces Mortality in the Presence of Antibiotic-Induced Tumor Necrosis Factor Release

Anti—Tumor Necrosis Factor Antibody Reduces Mortality in the Presence of Antibiotic-Induced Tumor... Abstract • The systemic tumor necrosis factor (TNF) response has been extensively studied during infection. In addition, antibiotics that cause cell-wall lysis have been associated with endotoxinemia and, therefore, could trigger TNF release. We studied the effects of pretreatment with cefoxitin and/or anti-TNF antibody on mortality and early (90 minutes) and delayed (6 hours) serum TNF levels in a murine model of mixed Escherichia coli/Bacteroides fragilis peritonitis. At low and intermediate inocula levels, cefoxitin, but not anti-TNF antibody, prevented death, and low serum TNF levels were noted in all groups. At the highest inoculum level, mortality was uniform in control, cefoxitin, and anti-TNF antibody groups, and a significant elevation in serum TNF levels was seen only at the 6-hour point in animals receiving cefoxitin. The addition of anti-TNF antibody to cefoxitin at this inoculum level abrogated the 6-hour rise in serum TNF levels and reduced mortality to 40%. These results emphasize that the cytokine response in disease is dependent on both the nature of the insult and other forms of therapeutic interventions. (Arch Surg. 1993;128:73-78) References 1. Michie HR, Wilmore DW. Sepsis and tumor necrosis factor: bedfellows that cannot be ignored . Ann Surg . 1990;212:653-654.Crossref 2. Rock CS, Lowry SF. Tumor necrosis factor-a . J Surg Res . 1991;51:434-445.Crossref 3. Michie HR, Maogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration . N Engl J Med . 1988;318: 1481-1486.Crossref 4. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from the lethal effect of endotoxin . Science . 1985;229:869-871.Crossref 5. Tracey KJ, Fong Y, Hesse DC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia . Nature . 1987;330: 662-664.Crossref 6. Mathison JC, Wolfson E, Elevitch RJ. Participation of tumor necrosis factor in the mediation of gram-negative bacterial lipopolysaccharide-induced injuries in rabbits . J Clin Invest . 1988;81:1925-1937.Crossref 7. Opal SM, Cross AS, Kelly NM, et al. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa . J Infect Dis . 1990;161:1148-1152.Crossref 8. Hinshaw LB, Tekamp-Olson P, Chang AC, et al. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor . Circ Shock . 1990;30:279-292. 9. Mayoral JL, Schweich CJ, Dunn DL. Decreased tumor necrosis factor production during the initial stages of infection correlates with survival during murine gram-negative sepsis . Arch Surg . 1990;125:24-27.Crossref 10. Mayoral JL, Dunn DL. Cross-negative murine monoclonal antibodies directed against the core/lipid A region of endotoxin inhibit production of tumor necrosis factor . J Surg Res . 1990;49:287-292.Crossref 11. Dunn DL. Development and potential use of antibody directed against lipopolysaccharide for the treatment of gram-negative bacterial sepsis . J Trauma . 1990;30:S100-S106.Crossref 12. Waage A, Halstensen A, Espevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease . Lancet . 1987;1:355-357.Crossref 13. Marano MA, Fong Y, Moldawer LL, et al. Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality . Surg Gynecol Obstet . 1990;170:32-36. 14. Exley AR, Cohen J, Buurman W, et al. Monoclonal antibody to TNF in severe septic shock . Lancet . 1990;335:1275-1277.Crossref 15. Reilly J, Compagnon A, Tournier P, Bastin R, Du Buit H. Les accidents du traitement des fièvres typhoïdes par la chloromycétine; étude expérimentale et déductions thérepeutiques . Ann Med . 1950;51:597-654. 16. Hopkin DAB. Frapper fort ou frapper doucement: a gram-negative dilemma . Lancet . 1978;2:1193-1194. 17. Goto H, Nukamura S. Liberation of endotoxin from Escherichia coli by addition of antibiotics . Jpn J Exp Med . 1980;50:35-39. 18. Shenep JL, Mogan KA. Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis . J Infect Dis . 1984; 150:380-388.Crossref 19. Tauber MG, Shibl AM, Hackbarth CJ, Larrick JW, Sande MA. Antibiotic therapy, endotoxin concentration in cerebrospinal fluid, and brain edema in experimental Escherichia coli meningitis in rabbits . J Infect Dis . 1987; 156:456-462.Crossref 20. Simon DM, Koenig G, Trenholme GM. Differences in release of tumor necrosis factor from THP-1 cells stimulated by filtrates of antibiotic-killed Escherichia coli . J Infect Dis . 1991;164:800-802.Crossref 21. Mustafa MM, Ramilo O, Mertsola J, et al. Modulation of inflammation and cachectin activity in relation to treatment of experimental Haemophilus influenzae type B meningitis . J Infect Dis . 1989;160:818-825.Crossref 22. Livingston DH, Malangoni MA, Sonnenfeld G. Immune enhancement by tumor necrosis factor-alpha improves antibiotic efficacy after hemorrhagic shock . J Trauma . 1989;29:967-971.Crossref 23. Malangoni MA, Livingston DH, Sonnenfeld G, Polk HC Jr. Interferon gamma and tumor necrosis factor alpha . Arch Surg . 1990;125:444-446.Crossref 24. Sawyer RG, Adams RB, May AK, Rosenlof LK, Spengler MD, Pruett TL. Interleukin-4 (IL-4) prevents mortality from acute but not chronic peritoneal infections and induces an accelerated tumor necrosis factor alpha (TNF) response . Surg Forum . 1991;42:93-96. 25. Brook I. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice . J Infect Dis . 1989;160:651-656.Crossref 26. Adams RB, Sawyer RG, May AK, Spengler MD, Pruett TL. Mixed bacterial and fungal intraperitoneal infections: antibacterial agents alone fail to reduce mortality . Surg Forum . 1991;42:72-73. 27. Sawyer RG, Adams RB, Spengler MD, Pruett TL. Pre-exposure of the peritoneum to live bacteria increases later mixed intraabdominal abscess formation and alters mortality . J Infect Dis . 1991;163:664-667.Crossref 28. Cross AS, Sadoff JC, Kelly N, Bernton E, Gemski P. Pretreatment with recombinant murine tumor necrosis factor-alpha/cachectin and murine interleukin-1 alpha protects mice from lethal bacterial infection . J Exp Med . 1989;169:2021-2027.Crossref 29. Sheppard BC, Fraker DL, Norton JA. Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor . Surgery . 1989;106:156-161. 30. Echtenacher B, Falk W, Männel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis . J Immunol . 1990;145:3762-3766. 31. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S. Divergent efficacy of antibody to tumor necrosis-alpha in intravascular and peritonitis models of sepsis . J Infect Dis . 1991;163:83-88.Crossref 32. Sheppard BC, Norton JA. Tumor necrosis factor and interleukin-1 protection against the lethal effects of tumor necrosis factor . Surgery . 1991; 109:698-705. 33. Alexander HR, Sheppard BC, Jansen JC, et al. Treatment with recombinant tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis . J Clin Invest . 1991;88: 34-39.Crossref 34. Ayala A, Perrin MM, Kisala J, Ertel W, Chaudry IH. Sepsis selectively activates peritoneal but not alveolar macrophages to release inflammatory mediators (IL-1, IL-6 and TNF) . Surg Forum . 1990;41:117-119. 35. Zamir O, Hasselgren P-O, Kunkel SL, Frederick J, Higashiguchi T, Fischer JE. Evidence that tumor necrosis factor participates in the regulation of muscle proteolysis during sepsis . Arch Surg . 1992;127:170-174.Crossref 36. Ayala A, Kisala JM, Felt JA, Perrin MM, Chaudry IH. Does endotoxin tolerance prevent the release of inflammatory monokines (interleukin 1, interleukin 6, or tumor necrosis factor) during sepsis? Arch Surg . 1992;127: 191-197.Crossref http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Archives of Surgery American Medical Association

Anti—Tumor Necrosis Factor Antibody Reduces Mortality in the Presence of Antibiotic-Induced Tumor Necrosis Factor Release

Download PDF
6 pages

Loading next page...
 
/lp/american-medical-association/anti-tumor-necrosis-factor-antibody-reduces-mortality-in-the-presence-vNIQRU0mbW

References (37)

Publisher
American Medical Association
Copyright
Copyright © 1993 American Medical Association. All Rights Reserved.
ISSN
0004-0010
eISSN
1538-3644
DOI
10.1001/archsurg.1993.01420130081013
Publisher site
See Article on Publisher Site

Abstract

Abstract • The systemic tumor necrosis factor (TNF) response has been extensively studied during infection. In addition, antibiotics that cause cell-wall lysis have been associated with endotoxinemia and, therefore, could trigger TNF release. We studied the effects of pretreatment with cefoxitin and/or anti-TNF antibody on mortality and early (90 minutes) and delayed (6 hours) serum TNF levels in a murine model of mixed Escherichia coli/Bacteroides fragilis peritonitis. At low and intermediate inocula levels, cefoxitin, but not anti-TNF antibody, prevented death, and low serum TNF levels were noted in all groups. At the highest inoculum level, mortality was uniform in control, cefoxitin, and anti-TNF antibody groups, and a significant elevation in serum TNF levels was seen only at the 6-hour point in animals receiving cefoxitin. The addition of anti-TNF antibody to cefoxitin at this inoculum level abrogated the 6-hour rise in serum TNF levels and reduced mortality to 40%. These results emphasize that the cytokine response in disease is dependent on both the nature of the insult and other forms of therapeutic interventions. (Arch Surg. 1993;128:73-78) References 1. Michie HR, Wilmore DW. Sepsis and tumor necrosis factor: bedfellows that cannot be ignored . Ann Surg . 1990;212:653-654.Crossref 2. Rock CS, Lowry SF. Tumor necrosis factor-a . J Surg Res . 1991;51:434-445.Crossref 3. Michie HR, Maogue KR, Spriggs DR, et al. Detection of circulating tumor necrosis factor after endotoxin administration . N Engl J Med . 1988;318: 1481-1486.Crossref 4. Beutler B, Milsark IW, Cerami AC. Passive immunization against cachectin/tumor necrosis factor protects mice from the lethal effect of endotoxin . Science . 1985;229:869-871.Crossref 5. Tracey KJ, Fong Y, Hesse DC, et al. Anti-cachectin/TNF monoclonal antibodies prevent septic shock during lethal bacteremia . Nature . 1987;330: 662-664.Crossref 6. Mathison JC, Wolfson E, Elevitch RJ. Participation of tumor necrosis factor in the mediation of gram-negative bacterial lipopolysaccharide-induced injuries in rabbits . J Clin Invest . 1988;81:1925-1937.Crossref 7. Opal SM, Cross AS, Kelly NM, et al. Efficacy of a monoclonal antibody directed against tumor necrosis factor in protecting neutropenic rats from lethal infection with Pseudomonas aeruginosa . J Infect Dis . 1990;161:1148-1152.Crossref 8. Hinshaw LB, Tekamp-Olson P, Chang AC, et al. Survival of primates in LD100 septic shock following therapy with antibody to tumor necrosis factor . Circ Shock . 1990;30:279-292. 9. Mayoral JL, Schweich CJ, Dunn DL. Decreased tumor necrosis factor production during the initial stages of infection correlates with survival during murine gram-negative sepsis . Arch Surg . 1990;125:24-27.Crossref 10. Mayoral JL, Dunn DL. Cross-negative murine monoclonal antibodies directed against the core/lipid A region of endotoxin inhibit production of tumor necrosis factor . J Surg Res . 1990;49:287-292.Crossref 11. Dunn DL. Development and potential use of antibody directed against lipopolysaccharide for the treatment of gram-negative bacterial sepsis . J Trauma . 1990;30:S100-S106.Crossref 12. Waage A, Halstensen A, Espevik T. Association between tumor necrosis factor in serum and fatal outcome in patients with meningococcal disease . Lancet . 1987;1:355-357.Crossref 13. Marano MA, Fong Y, Moldawer LL, et al. Serum cachectin/tumor necrosis factor in critically ill patients with burns correlates with infection and mortality . Surg Gynecol Obstet . 1990;170:32-36. 14. Exley AR, Cohen J, Buurman W, et al. Monoclonal antibody to TNF in severe septic shock . Lancet . 1990;335:1275-1277.Crossref 15. Reilly J, Compagnon A, Tournier P, Bastin R, Du Buit H. Les accidents du traitement des fièvres typhoïdes par la chloromycétine; étude expérimentale et déductions thérepeutiques . Ann Med . 1950;51:597-654. 16. Hopkin DAB. Frapper fort ou frapper doucement: a gram-negative dilemma . Lancet . 1978;2:1193-1194. 17. Goto H, Nukamura S. Liberation of endotoxin from Escherichia coli by addition of antibiotics . Jpn J Exp Med . 1980;50:35-39. 18. Shenep JL, Mogan KA. Kinetics of endotoxin release during antibiotic therapy for experimental gram-negative bacterial sepsis . J Infect Dis . 1984; 150:380-388.Crossref 19. Tauber MG, Shibl AM, Hackbarth CJ, Larrick JW, Sande MA. Antibiotic therapy, endotoxin concentration in cerebrospinal fluid, and brain edema in experimental Escherichia coli meningitis in rabbits . J Infect Dis . 1987; 156:456-462.Crossref 20. Simon DM, Koenig G, Trenholme GM. Differences in release of tumor necrosis factor from THP-1 cells stimulated by filtrates of antibiotic-killed Escherichia coli . J Infect Dis . 1991;164:800-802.Crossref 21. Mustafa MM, Ramilo O, Mertsola J, et al. Modulation of inflammation and cachectin activity in relation to treatment of experimental Haemophilus influenzae type B meningitis . J Infect Dis . 1989;160:818-825.Crossref 22. Livingston DH, Malangoni MA, Sonnenfeld G. Immune enhancement by tumor necrosis factor-alpha improves antibiotic efficacy after hemorrhagic shock . J Trauma . 1989;29:967-971.Crossref 23. Malangoni MA, Livingston DH, Sonnenfeld G, Polk HC Jr. Interferon gamma and tumor necrosis factor alpha . Arch Surg . 1990;125:444-446.Crossref 24. Sawyer RG, Adams RB, May AK, Rosenlof LK, Spengler MD, Pruett TL. Interleukin-4 (IL-4) prevents mortality from acute but not chronic peritoneal infections and induces an accelerated tumor necrosis factor alpha (TNF) response . Surg Forum . 1991;42:93-96. 25. Brook I. In vitro susceptibility and in vivo efficacy of antimicrobials in the treatment of Bacteroides fragilis-Escherichia coli infection in mice . J Infect Dis . 1989;160:651-656.Crossref 26. Adams RB, Sawyer RG, May AK, Spengler MD, Pruett TL. Mixed bacterial and fungal intraperitoneal infections: antibacterial agents alone fail to reduce mortality . Surg Forum . 1991;42:72-73. 27. Sawyer RG, Adams RB, Spengler MD, Pruett TL. Pre-exposure of the peritoneum to live bacteria increases later mixed intraabdominal abscess formation and alters mortality . J Infect Dis . 1991;163:664-667.Crossref 28. Cross AS, Sadoff JC, Kelly N, Bernton E, Gemski P. Pretreatment with recombinant murine tumor necrosis factor-alpha/cachectin and murine interleukin-1 alpha protects mice from lethal bacterial infection . J Exp Med . 1989;169:2021-2027.Crossref 29. Sheppard BC, Fraker DL, Norton JA. Prevention and treatment of endotoxin and sepsis lethality with recombinant human tumor necrosis factor . Surgery . 1989;106:156-161. 30. Echtenacher B, Falk W, Männel DN, Krammer PH. Requirement of endogenous tumor necrosis factor/cachectin for recovery from experimental peritonitis . J Immunol . 1990;145:3762-3766. 31. Bagby GJ, Plessala KJ, Wilson LA, Thompson JJ, Nelson S. Divergent efficacy of antibody to tumor necrosis-alpha in intravascular and peritonitis models of sepsis . J Infect Dis . 1991;163:83-88.Crossref 32. Sheppard BC, Norton JA. Tumor necrosis factor and interleukin-1 protection against the lethal effects of tumor necrosis factor . Surgery . 1991; 109:698-705. 33. Alexander HR, Sheppard BC, Jansen JC, et al. Treatment with recombinant tumor necrosis factor-alpha protects rats against the lethality, hypotension, and hypothermia of gram-negative sepsis . J Clin Invest . 1991;88: 34-39.Crossref 34. Ayala A, Perrin MM, Kisala J, Ertel W, Chaudry IH. Sepsis selectively activates peritoneal but not alveolar macrophages to release inflammatory mediators (IL-1, IL-6 and TNF) . Surg Forum . 1990;41:117-119. 35. Zamir O, Hasselgren P-O, Kunkel SL, Frederick J, Higashiguchi T, Fischer JE. Evidence that tumor necrosis factor participates in the regulation of muscle proteolysis during sepsis . Arch Surg . 1992;127:170-174.Crossref 36. Ayala A, Kisala JM, Felt JA, Perrin MM, Chaudry IH. Does endotoxin tolerance prevent the release of inflammatory monokines (interleukin 1, interleukin 6, or tumor necrosis factor) during sepsis? Arch Surg . 1992;127: 191-197.Crossref

Journal

Archives of Surgery – American Medical Association

Published: Jan 1, 1993

There are no references for this article.